Hanmi Pharmaceutical Rises Even on the Stock Market’s ‘Black Friday’ ... Hopes for Domestic Obesity Drug ‘Epe’ [Stock Now]
- Input
- 2026-11-20 14:28:20
- Updated
- 2026-11-20 14:28:20

[Financial News] As South Korea’s stock market plunges and investor sentiment freezes, Hanmi Pharmaceutical is bucking the trend.
The Kospi and Kosdaq have fallen more than 5% amid a shock from U.S. technology stocks and heavy selling by foreign investors and institutions, but Hanmi Pharmaceutical is rising as expectations for the commercialization of its self-developed obesity treatment ‘Epe’ and its clinical results come into focus.
As of 2:16 p.m. on the 20th, Hanmi Pharmaceutical was trading on the main board at 451,500 won, up 29,500 won (6.99%) from the previous trading day. It climbed as high as 467,500 won during the session. This contrasted with a broad plunge in South Korea’s stock market, with the Kospi down 5.58% and the Kosdaq down 5.43% at the same time.
Expectations for the commercialization of Epe, a homegrown GLP-1 obesity treatment, are cited as a reason for the share-price rise. Hanmi Pharmaceutical began prescribing Epe in South Korea on the 29th of last month. As a domestic novel drug enters a market previously led by imported obesity treatments, attention is focused on the potential for prescriptions to ramp up early and for the drug to gain a foothold.
The recently released long-term clinical results are also thought to have boosted investor sentiment. On the 16th, Hanmi Pharmaceutical presented results from 64 weeks of treatment in Epe’s domestic Phase 3 trial at a meeting of an obesity society in the United States.
A study of 448 Korean adults with obesity or overweight found an average weight reduction of 10.56%. That was 0.81 percentage points higher than the previous interim result at 40 weeks, which was 9.75%.
This is significant as additional evidence confirming the effects of long-term treatment with Epe. With interest growing in the drug’s prescription performance early after launch and long-term clinical data providing further support, the share price appears to reflect expectations that it can secure a competitive position in South Korea’s obesity treatment market.
The market is watching not only to see whether Epe can gain a foothold in South Korea but also Hanmi Pharmaceutical’s follow-on obesity drug pipeline. As the global obesity treatment market grows rapidly, whether the company can build experience commercializing homegrown novel drugs and achieve development success with its next candidates is seen as key to a reassessment of its corporate value.
[email protected] Kang Jung-mo Reporter